For Patients

Multifocal motor neuropathy (MMN)

Multifocal motor neuropathy (MMN) is a progressively worsening condition where muscles in the extremities gradually weaken. The disorder, a pure motor neuropathy syndrome, is sometimes mistaken for amyotrophic lateral sclerosis (ALS) because of the similarity in the clinical picture, especially if muscle fasciculations are present. MMN is thought to be autoimmune.

It was first described in the mid-1980s. Unlike ALS which affects both upper and lower motor nerves, MMN involves only lower motor nerves. Nevertheless, definitive diagnosis is often difficult, and many MMN patients labor for months or years under an ALS diagnosis before finally getting a determination of MMN. MMN usually involves very little pain; however, muscle cramps, spasms and twitches can cause pain for some sufferers. MMN is not fatal and does not diminish life expectancy.

Many patients, once undergoing treatment, only experience mild symptoms over prolonged periods, though the condition remains slowly progressive. MMN can however, lead to significant disability, with loss of function in hands affecting ability to work and perform everyday tasks, and “foot drop” leading to inability to stand and walk; some patients end up using aids like canes, splints and walkers.

Treatments

Multifocal motor neuropathy is normally treated by receiving intravenous immunoglobulin (Immune Globulin Therapy), which can in many cases be highly effective, or immunosuppressive therapy with cyclophosphamide or rituximab. Steroid treatment (prednisone) and plasmapheresis are no longer considered to be useful treatments; prednisone can exacerbate symptoms. Immune Globulin Therapy is the primary treatment, with about 80% of patients responding, usually requiring regular infusions at intervals of 1 week to several months. Subcutaneous immunoglobulin is under study as a less invasive, more-convenient alternative to IV delivery.

More Information

please visit the GBS/CIDP Foundation International at https://www.gbs-cidp.org/

please visit the Neuropathy Action Foundation at http://www.neuropathyaction.org/

Products We Offer

Immune Globulin Therapy

Immune globulin is made from pooled plasma collected from thousands of donors and treated to remove contaminants to ensure product safety and integrity. Containing antibodies against a broad spectrum of bacteria and viruses, IVIG is administered intravenously and is used primarily to treat three categories of illnesses: primary immune deficiency diseases, autoimmune diseases and certain neurological disorders.
  • Carimune® NFCSL
    Behring
  • Flebogamma® DIF 5%
    Grifols
  • Flebogamma® DIF 10%
    Grifols
  • GAMMAGARD S/D
    Takeda
  • GAMMAGARD S/D (IGA<1 MCG/ML)
    Takeda
  • GAMMAGARD LIQUID
    Takeda
  • GAMMAKED™
    Kedrion
  • Gamunex®-C
    Grifols
  • Octagam® 5%
    Octapharma
  • Octagam® 10%
    Octapharma
  • Privigen®CSL
    Behring
  • Panzyga®
    Pfizer
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Corticosteroids

Contact CSI Pharmacy for more information on Corticosteroids.

Immune Globulin Therapy

Immune globulin is made from pooled plasma collected from thousands of donors and treated to remove contaminants to ensure product safety and integrity. Containing antibodies against a broad spectrum of bacteria and viruses, IVIG is administered intravenously and is used primarily to treat three categories of illnesses: primary immune deficiency diseases, autoimmune diseases and certain neurological disorders.

  • Carimune® NF
    CSL Behring
  • Flebogamma® DIF 5%
    Grifols
  • Flebogamma® DIF 10%
    Grifols
  • GAMMAGARD S/D
    Takeda
  • GAMMAGARD S/D (IGA<1 MCG/ML)
    Takeda
  • GAMMAGARD LIQUID
    Takeda
  • GAMMAKED™
    Kedrion
  • Gamunex®-C
    Grifols
  • Octagam® 5%
    Octapharma
  • Octagam® 10%
    Octapharma
  • Privigen®
    CSL Behring
  • Panzyga®
    Pfizer

Immune globulin is made from pooled plasma collected from thousands of donors and treated to remove contaminants to ensure product safety and integrity. Containing antibodies against a broad spectrum of bacteria and viruses, SCIG is administered subcutaneously and is approved to treat primary immune deficiencies and chronic inflammatory demyelinating polyneuropathy. It is also in clinical trials for autoimmune diseases.

  • GAMMAGARD LIQUID
    Takeda
  • GAMMAKED™
    Kedrion
  • Gamunex®-C
    Grifols
  • Hizentra®
    CSL Behring
  • HYQVIA®
    Takeda